Media coverage about Endologix (NASDAQ:ELGX) has been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern identifies negative and positive press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Endologix earned a news impact score of 0.21 on Accern’s scale. Accern also gave news headlines about the medical instruments supplier an impact score of 45.9707742771269 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
Several research firms have issued reports on ELGX. Zacks Investment Research cut Endologix from a “hold” rating to a “sell” rating in a research note on Tuesday, January 30th. Canaccord Genuity restated a “hold” rating and set a $5.00 price target on shares of Endologix in a research report on Wednesday, November 8th. Piper Jaffray Companies restated an “overweight” rating on shares of Endologix in a research report on Tuesday, December 12th. BidaskClub lowered Endologix from a “hold” rating to a “sell” rating in a research report on Friday, January 19th. Finally, ValuEngine lowered Endologix from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Four analysts have rated the stock with a sell rating, seven have issued a hold rating and one has issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $5.41.
Shares of Endologix (NASDAQ ELGX) traded down $0.03 during midday trading on Friday, reaching $4.17. The company’s stock had a trading volume of 548,948 shares, compared to its average volume of 588,985. The company has a debt-to-equity ratio of 2.61, a current ratio of 2.90 and a quick ratio of 2.11. Endologix has a 12 month low of $4.05 and a 12 month high of $7.66. The stock has a market cap of $348.00, a P/E ratio of -4.48 and a beta of 0.42.
Endologix (NASDAQ:ELGX) last posted its earnings results on Tuesday, November 7th. The medical instruments supplier reported ($0.11) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.06. Endologix had a negative return on equity of 52.18% and a negative net margin of 41.60%. The business had revenue of $45.99 million for the quarter, compared to analysts’ expectations of $47.21 million. equities analysts anticipate that Endologix will post -0.68 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Endologix (NASDAQ:ELGX) Given Media Impact Score of 0.21” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/04/endologix-elgx-receives-news-sentiment-rating-of-0-21.html.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.